A Phase 4 interventional study of Restrata and Negative Pressure Wound Therapy (NPWT) in Diabetic Wound, sponsored by University of Texas Southwestern Medical Center. Withdrawn at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-07-24.
Sponsored by University of Texas Southwestern Medical Center · Phase 4, Interventional, and Treatment
The purpose of this study is to compare the efficacy of Restrata compared to Negative Pressure Wound Therapy (NPWT) to heal complex diabetic foot wounds.
Screening
Baseline (may be done as same day as screening procedures)
Therapy/Treatment Phase
Study Visit 1-11:
Study Visit Closed
Study Visit 12/EOS:
Study Visit Follow-up
5,056 studies on the registry are indexed under Wounds and Injuries; 861 are open to participants now.
Browse Wounds and Injuries studies →University of Texas Southwestern Medical Center is the lead sponsor of 990 studies on the registry; 201 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 100 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Treated with Restrata
Device: Restrata
Treated with NPWT (Negative Pressure Wound Therapy)
Device: Negative Pressure Wound Therapy (NPWT)
Restrata® is a novel synthetic nanofabricated scaffold (Restrata Wound Matrix (RWM), Acera Surgical, St. Louis, Missouri) has been developed which is a sterile, single-use device intended for use in the local management of wounds. The RWM is a soft, white, conformable, non-friable, absorbable matrix that acts as a protective covering for wound defects, providing a moist environment for the body's natural healing process to occur (Figure 2). The RWM is made from synthetic biocompatible materials and was designed to include a fibrous structure with high porosity, similar to native ECM. As a viable wrap for surgical procedures, Restrata conforms to injured tissue, can be sutured, and is arthroscopic and robotic procedure friendly.
Negative Pressure Wound Therapy (NPWT) has dramatically changed the care of complex foot wounds. Compared to standard wound care, patients with diabetic foot wounds that are treated with NPWT are 5.9 times more likely to heal and 4.4 times less likely to require amputation. NPWT involves the delivery of sub-atmospheric pressure through a vacuum pump connected to a specialized dressing to maintain a closed environment. NPWT increases perfusion to the wound, accelerates granulation tissue formation, reduces edema, and reduces bio-burden
Wound Closure
The primary objective of this trial is to evaluate the incidence of wound closure. Closure is defined as complete epithelialization with no drainage.
Time frame: 12 weeks
Time to wound healing
Days to complete closure. Closure is defined as complete epithelialization with no drainage.
Time frame: 12 weeks
Differences in wound healing trajectories
Defined as the change in wound area per week. Measured by wound measuring camera and PI observation/physical exam. Reported as mm\^2 per day.
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Texas Southwestern Medical Center